A proposal to remove hospice providers from a state review poses a threat to patient care
Sign up to get breaking news and interesting stories from Rhode Island in your inbox each weekday.
Enter Email
Sign Up
The CON process isn't one of the flashier, public-facing functions of state government, but it has a direct impact on the quality of health and hospice care that Rhode Islanders receive throughout their lives.
Advertisement
The CON process is used to determine the need for a particular health care service and to ensure that providers entering Rhode Island are prepared and equipped to provide the highest quality, most ethical care before receiving a license.
Exempting hospice from meeting the rigorous standards that a CON requires poses an immediate threat to the quality of patient care.
Advertisement
In fact, extensive
In the last decade, profit-driven private equity firms have spent more than
Recently, based on increased reports of hospice fraud, waste and abuse, the Centers for Medicare and Medicaid Services (CMS) announced
All of this is a warning for Rhode Island. To roll back Certificate of Need requirements for hospice providers exposes vulnerable Rhode Islanders to the whims of anonymous, for-profit operators who put profit first, and patient care a distant second. Research has demonstrated that states with CON requirements have much higher quality of hospice care.
When we opened in 1976, HopeHealth was only the second hospice in the United States. As the leader of this nonprofit organization, I can tell you that this work is not about maximizing profits. It's a calling.
On behalf of our patients, their families, and our employees, we strongly urge the General Assembly not to weaken Rhode Island's Certificate of Need process. Instead, we should recommit to maintaining the high-quality hospice system that provides a level of care that Rhode Islanders have come to expect — and deserve — from their hospice providers by keeping hospice in CON.
Advertisement
Diana Franchitto is the president and CEO of HopeHealth Hospice & Palliative Care.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Roger Williams, Our Lady of Fatima hospitals sale to move forward. Here's why
PROVIDENCE – Attorney General Peter Neronha announced Thursday, July 31 an amended decision to facilitate the sale of Roger Williams Medical Center and Our Lady of Fatima Hospital. The decision – the second amended in the sale process – reduces the cash-on-hand requirement for the Centurion Foundation, a Georgia-based nonprofit, from $80 million to $45 million for closing the deal. The reduction of cash-on-hand, explained Neronha at a press conference, was due to Centurion having difficulties selling bonds to raise funds for the purchase of the hospitals. But the amended decision also requires Centurion and CharterCARE to secure an additional $35 million within 90 days, bringing the funds back to $80 million. Neronha said the parties have given him assurances on their ability to raise funds post-sale that, in his judgment, could be relied on. The attorney general also said he secured the remaining $50 million – from an original $80 million in an escrow account – to create a hospital fund as part of the transaction. Additional conditions have also been attached to the sale, among them: A requirement for the parties to spend at least $50 million on capital expenses at the hospitals within three years of the transaction A requirement for the parties to not contest the attorney general's right to file a petition for the appointment of a receiver in case of insolvency The detainment of a consultant, at the expense of the parties, to report on the financial and operation state of the hospitals 'While this is a complicated process, our goal is simple: make sure our safety net hospitals are in the best position possible to serve our communities for as long as possible,' Neronha said in a written statement following the press event. Neronha explained that the hospitals were not yet entirely out of danger but that progress has been made: the hospitals are staying provisionally open, are shifting from for-profit to nonprofit and the attorney general's office will have levers to pull in case of an insolvency. 'I don't want to stand here and gaslight Rhode Islanders and make them believer, or have them believe, that all the problems have been solved. They haven't,' Neronha said at the July 31 press conference. 'But we have made some steps forward.' The attorney general added that Rhode Island's chronic low reimbursement rates from public and private insurance need to be addressed to treat the health system's ailments. 'Until we make a Rhode Island patient mean the same financially as a Massachusetts or a Connecticut patient, our hospital systems and our providers and our workers are always going to be at a state of disadvantage,' Neronha said. The anticipated closing date for the sale – pending approval by a bankruptcy court in Texas – is sometime in late August or mid-September. The full amended decision is available here. This article originally appeared on The Providence Journal: Roger Williams, Our Lady of Fatima hospital sales moving forward Solve the daily Crossword
Miami Herald
14 hours ago
- Miami Herald
Millions of Medicare beneficiaries are facing a rude awakening
Millions of Medicare beneficiaries are on the brink of an unwelcome surprise regarding their prescription drug costs. After the Medicare Trustees' 2025 report declared Part D prescription drug coverage to be in "satisfactory financial condition," the Centers for Medicare & Medicaid Services (CMS) is now taking emergency action to contain skyrocketing premiums for 2026. Don't miss the move: SIGN UP for TheStreet's FREE daily newsletter The crisis underscores how fragile the program has become - and why beneficiaries will need to be more proactive than ever this fall. Image source: bernard buyse on Unsplash Despite the Trustees' rosy projections, insurers submitted 2026 Part D bids with dramatic premium increases. The National Average Monthly Bid Amount (NAMBA) soared from $179.45 in 2025 to $239.27, threatening base premiums well beyond what beneficiaries might tolerate. If 2025 is any guide, however, the 2026 base beneficiary premium will be far less than the eye-popping $239.27 NAMBA. In 2025, the NAMBA was $179.45 - yet the base premium was just $36.78. Understanding the national average monthly bid amount NAMBA is a figure used by the CMS to help determine the costs and subsidies for Medicare Part D prescription drug plans. In simple terms, it's the average cost that all participating insurance plans estimate it will take to provide basic prescription drug coverage for one person for one month. The "average" is weighted by the number of people enrolled in each plan. Related: Millions of Medicare beneficiaries could see major price shock For the first time in the program's history, CMS rejected some standalone Part D plan bids, citing "unacceptable, significant increases in cost sharing or reductions in benefits." The agency also extended its emergency Premium Stabilization Demonstration, which caps how much monthly premiums can rise, though the cap will increase to $50 in 2026 from $35 in 2025. The Inflation Reduction Act's unintended consequences: How policy shifts are driving up your costs So, what went wrong? Much of the turbulence stems from the Inflation Reduction Act (IRA), which was designed to help seniors by capping out-of-pocket drug spending. The law's 2025 benefit redesign introduced: A $2,000 annual out-of-pocket cap (rising to $2,100 in 2026).Increased government liability for catastrophic pricing pressures on insurers. While the cap benefits the roughly 5% of beneficiaries with the highest annual drug costs, the vast majority - about 95% - now face higher deductibles, increased coinsurance, and volatile premiums. According to KFF, 85% of PDP enrollees face deductibles in 2025, up from 67% a year earlier. Coinsurance: The hidden cost that could skyrocket your drug bills The result is a market under stress. Some Medicare Part D enrollees face coinsurance instead of flat copays, meaning they pay a percentage of a drug's retail price – often 25% to 33% – rather than a fixed dollar amount. Coinsurance is most common for non-preferred and specialty drugs, not for standard preferred brands. Take Eliquis as an illustration of the math: Its retail cost can exceed $700 a month. If a plan required 25% coinsurance, that would be about $178 per month, and 33% would run $235 - far higher than the typical $47 flat copay charged when Eliquis is classified as a preferred brand. While most plans currently use copays for this drug, retirees need to understand that coinsurance on higher-cost medications can create significant out-of-pocket exposure. As costs shift to consumers, federal interventions are doing the heavy lifting to prevent widespread premium shock. "Automatic financing" - the Trustees' faith that Treasury transfers would always smooth things out - isn't enough to stabilize the market under the IRA's redesign. The average 2025 standalone Part D premium actually fell to $39 a month, but that stability is artificial - propped up by temporary subsidies and bid caps. Behind the scenes, plan choices are shrinking, and market concentration is increasing. The top five firms now control nearly three-quarters of enrollment. Low-income subsidy decline: A shrinking safety net for vulnerable seniors Low-income beneficiaries are also feeling the squeeze. Enrollment in the Low-Income Subsidy (LIS) program dropped from 13.7 million to 13.1 million in 2025, partly due to Medicaid "unwinding." Fewer people are shielded from the volatility. Related: Retired workers to see frustrating change to Medicare in 2026 This is the new Part D reality - volatile premiums, higher deductibles, and a market reliant on emergency federal action. With open enrollment for 2026 coverage beginning Oct. 15, inaction could cost you thousands. Historically, most beneficiaries stick with the same drug plan year after year, but that complacency is now dangerous. The reshop imperative: Why annual review is non-negotiable "It will be more important than ever for Medicare beneficiaries to 'reshop' their Part D drug plans during open enrollment this fall," said Mary Beth Franklin, a certified financial planner and Medicare expert. "Base your decision on your specific drugs and dosages - not last year's premium." Practical steps for beneficiaries 1. Review your Annual Notice of Change (ANOC): Plans will mail these in September. They spell out changes to premiums, deductibles, formularies, and pharmacy networks. Even small shifts can have big financial impacts. 2. Use the Medicare Plan Finder tool: Available at starting Oct. 1, the tool lets you enter your prescriptions, dosage, ZIP code, and preferred pharmacy to compare total annual costs across plans. Focus on total out-of-pocket cost, not just the monthly premium. Navigating fewer choices: The impact of market consolidation Fewer plan options mean less room for error. According to Melinda Caughill, co-founder of 65 Incorporated, "We had an average of 22 plan options at the end of 2024. In 2025, there are just 14." Real savings: What you could save by comparing plans Caughill reports some clients have saved an average of $8,000 by switching plans - with extreme cases topping $100,000 over time. "Assuming that, because the coverage worked for you this year, it will work next year is utter nonsense," she said. Seeking professional guidance: When to get help Professional guidance may be harder to find. Several major carriers have cut agent commissions for Part D plans, reducing the availability of free expert assistance. If you need help, schedule it early or consider paying a professional for an independent review. Consider buying your prescriptions off-plan While you are generally better off having a Part D plan, and you'll avoid future penalties, you do not have to use it to pay for your drugs, said Marcia Mantell, president of Mantell Retirement Consulting. "If you see there's a big increase in a prescription you must take, check out any of the off-plan options available to you at no cost: GoodRx, Singlecare, AARP's discount drug card, Amazon, Mark Cuban's Cost Plus Drug Company, and many more. It takes more time, but there could be big savings." Don't forget Part B premiums: Another cost to consider In addition to Part D changes, standard Part B premiums are projected to rise sharply in 2026. Make sure to factor the combined cost of Medicare into your budget. Medicare Part D is entering a period of unprecedented volatility. Federal interventions are temporarily softening the blow, but the underlying market is fragile. For most beneficiaries, the best defense is active shopping during open enrollment - comparing plans, understanding coinsurance exposure, and making sure your plan still works for your prescriptions and your budget. Failure to act could turn 2026 into the most expensive year yet for your prescription drugs. The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Boston Globe
19 hours ago
- Boston Globe
‘We're not in a good place': R.I. attorney general looks to speed up sale of Roger Williams, Fatima hospitals
'I can't stand here today and tell Rhode Islanders... that these hospitals will be running and robust 18 months from now. I don't know that,' Neronha said at a press conference on Thursday. 'We have two hospitals here, who frankly could have actually closed.' Get Rhode Map A weekday briefing from veteran Rhode Island reporters, focused on the things that matter most in the Ocean State. Enter Email Sign Up Prospect Medical Holdings, a for-profit hospital chain that operates safety-net hospitals including Roger Williams and Fatima, Since late 2022, Prospect has been trying to sell its two Rhode Island hospitals. In June 2024, Rhode Island state regulators approved the terms of a deal to sell them to The Centurion Foundation, which is based in Georgia. Their approval came Advertisement Centurion's counsel approached Neronha this month to negotiate. 'Centurion was having difficulty selling bonds for that initial hospital funding bucket,' he said. Under the revised conditions, Centurion will need to have $45 million in cash to take over the hospitals, which is down from $80 million that was previously required in Neronha's June 2024 conditions. In addition, Centurion has agreed to secure up to $35 million within 90 days of closing. 'This is an important step forward as we move through the bond and financing process and finalizing the sale to help secure the future of these essential hospitals and 2,400 employees,' said Otis Brown, a spokesperson for the Rhode Island hospitals and for The Centurion Foundation. Neronha will require that Centurion and the new system formed after the sale not contest his office if it files a petition to appoint a receiver of the new system if it fails to pay any principal or interest under any future bond financing. Prospect also owns hospitals in Pennsylvania and three hospitals in Connecticut. The hospitals in Pennsylvania are being sold off as real estate assets, because they could not identify a buyer, said Neronha. The fate of the hospitals in Connecticut 'remain up in the air,' Neronha said. While Prospect has struggled to sell off its hospitals in other states, the challenges it faces in Rhode Island should be seen in the larger context of how its difficult to operate health care businesses in the state, Neronha said. Advertisement 'We are not in a good place,' said Neronha. Alexa Gagosz can be reached at
